Cambridge Healthtech Institute’s 12th Annual

Vaccine Adjuvants

Improving Vaccine Response through Advanced Technologies
August 31-September 1, 2017 | Sheraton Boston | Boston, MA

Many recently developed vaccines are comprised of recombinant molecules or subunits of pathogenic organisms, requiring formulation with adjuvants to increase and direct the immune response. The benefit of adjuvants is clear: they may reduce the amount of antigen and number of vaccinations needed, accelerate the immune response, increase cross-protection, and improve efficacy in populations that are poor responders. As we continue to confront emerging and re-emerging disease threats and progress toward developing new vaccines to improve global health, there is also an urgent need for the development of effective adjuvants. CHI’s Twelfth Annual Vaccine Adjuvants meeting will cover the latest advances in a range of adjuvants and present a look at future development.

Preliminary Agenda


UNDERSTANDING AND MODELING HUMAN IMMUNITY

Modeling of Age-Specific Human Immunity in vitro for Discovery of Small Molecule Adjuvants

Ofer Levy, M.D., Ph.D., Director, Precision Vaccine Program, Boston Children’s Hospital; Associate Professor, Pediatrics, Harvard Medical School

STING-Dependent Innate Immune Signaling and Cancer

Glen N. Barber, Ph.D., Professor & Chair, Cell Biology, University of Miami Miller School of Medicine

Cellular Effectors of the Humoral Immune Response

Daniel Lingwood, Ph.D., Assistant Professor, Medicine, Harvard Medical School


VACCINE ADJUVANTS IN CANCER

Vaccine Adjuvants in Cancer and Other Immunotherapy Applications

Nikolai Petrovsky, MBBS, Ph.D., Chairman & Research Director, Vaxine; Professor, Flinders University

Archaeal Lipid Adjuvant Systems for Cancer Vaccine Development

Lakshmi Krishnan, Ph.D., Director & Program Leader, Vaccines and Immunotherapeutics, National Research Council, Canada

Development of an Immunotherapeutic Vaccine for Curing Large Solid Tumors in Mice

Joost Oppenheim, M.D., Senior Investigator, Cancer and Inflammation Program, Head, Cellular Immunology Section, National Cancer Institute, National Institutes of Health


NUCLEIC ACIDS AS VACCINE ADJUVANTS

Selective RIG-I Agonists as Antivirals and Vaccine Adjuvants

Anna Marie Pyle, Ph.D., William Edward Gilbert Professor, Molecular, Cellular & Developmental Biology, Yale University


NANOPARTICLE ADJUVANTS

Investigating Lipid Nanoparticle Formulations in the Context of Infectious Diseases & Immuno-Oncology

Gokul Swaminathan, Ph.D., Immuno-Biology Group, Merck Exploratory Science Center, Merck & Co., Inc.


LYOPHILIZATION OF ADJUVANTED VACCINES

Feasibility of Freeze Drying of Oil-in-Water Emulsion Adjuvants

Vidyashankara Iyer, Ph.D., Scientist, Formulation Sciences, MedImmune




For more details on the conference, please contact:
Virginia Maxwell
Senior Associate Producer
781-972-5436
vmaxwell@healthtech.com

For exhibit & sponsorship opportunities, please contact: 
 
Rod Eymael
Manager, Business Development
781-247-6286
reymael@healthtech.com

YouTubeOutlookYouTubeLinkedInTwitter #IOSummit  

Japan-Flag   Korea-Flag   China-Simplified-Flag   China-Traditional-Flag

Register Today